^
Association details:
| Biomarker: | ROS1 positive |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | APG-2449 (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
APG-2449 in Patients With Advanced Solid Tumors
Excerpt:
...cohort two, ALK/ROS1 fusion gene positive without TKI treatment Patients with non-small cell lung cancer....
Trial ID:
Source:
Title:
FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.
Published date:
05/25/2023
Excerpt:
...the overall response rate (ORR) and the disease control rate (DCR = CR + PR + SD) were 70.6% (12/17) and 88.2% (15/17), respectively, in ROS1+ treatment naïve pts; the ORR and DCR were 78.6% (11/14) and 100% (14/14) in ALK+ treatment naïve pts….APG-2449 showed a favorable preliminary safety profile and antitumor efficacy in pts with NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.9015
Trial ID:
Source:
Title:
First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma.
Published date:
05/26/2022
Excerpt:
...APG-2449 in patients with second-generation TKI-resistant ALK/ROS1+ NSCLC or mesothelioma....Four partial responses (PRs) were observed in 14 ALK+ pts resistant to second-generation TKIs treated at the RP2D....In 10 TKI-naïve pts, the overall response rate was 80% (ALK+, 6/8; ROS1+, 2/2) and the disease control rate (DCR) was 100%.
DOI:
10.1200/JCO.2022.40.16_suppl.9071
Trial ID:
